Manulife (Manufacturers Life Insurance)
ZVRA icon

Manulife (Manufacturers Life Insurance)’s Zevra Therapeutics ZVRA Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Sell
15,137
-1,759
-10% -$15.9K ﹤0.01% 2550
2025
Q4 		$151K Sell
16,896
-1,768
-9% -$16.7K ﹤0.01% 2620
2025
Q3 		$177K Sell
18,664
-1,630
-8% -$16.3K ﹤0.01% 2624
2025
Q2 		$179K Buy
20,294
+1,750
+9% +$14.2K ﹤0.01% 2600
2025
Q1 		$139K Buy
18,544
+903
+5% +$7.18K ﹤0.01% 2608
2024
Q4 		$147K Sell
17,641
-267
-1% -$2.28K ﹤0.01% 2725
2024
Q3 		$124K Sell
17,908
-665
-4% -$4.51K ﹤0.01% 2804
2024
Q2 		$91K Buy
18,573
+2,452
+15% +$11.6K ﹤0.01% 2848
2024
Q1 		$93.5K Buy
16,121
+342
+2% +$2.1K ﹤0.01% 2790
2023
Q4 		$103K Hold
15,779
– – ﹤0.01% 2812
2023
Q3 		$76.1K Hold
15,779
– – ﹤0.01% 2881
2023
Q2 		$80.5K Buy
+15,779
New +$85K ﹤0.01% 2915
2022
Q2 		– Sell
-13,939
Closed -$70.1K – 3157
2022
Q1 		$70.1K Sell
13,939
-3,825
-22% -$24.3K ﹤0.01% 3011
2021
Q4 		$155 Buy
17,764
+3,122
+21% +$27.9K ﹤0.01% 2979
2021
Q3 		$137K Sell
14,642
-1,908
-12% -$19.2K ﹤0.01% 3078
2021
Q2 		$212K Buy
+16,550
New +$178K ﹤0.01% 3067
2017
Q3 		– Sell
-26
Closed -$2K – 4352
2017
Q2 		$2K Sell
26
-2
-7% -$132 ﹤0.01% 4144
2017
Q1 		$2K Hold
28
– – ﹤0.01% 3967
2016
Q4 		$1K Hold
28
– – ﹤0.01% 4244
2016
Q3 		$2K Hold
28
– – ﹤0.01% 4086
2016
Q2 		$2K Hold
28
– – ﹤0.01% 4024
2016
Q1 		$7K Buy
+28
New +$6.78K ﹤0.01% 3724

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ZVRA Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Zevra Therapeutics (ZVRA) stake by 10% in Q1 2026, selling an estimated $15.9K and leaving 15,137 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #2550.

Manulife (Manufacturers Life Insurance) first reported a position in ZVRA in Q1 2016 and has held it in 22 quarters since. The position peaked at $212K in Q2 2021. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 15,137 shares of Zevra Therapeutics worth $141K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 1,759 Zevra Therapeutics shares in Q1 2026, an estimated $15.9K.
  • Zevra Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2550 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Zevra Therapeutics in Q1 2016 and has held it in 22 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Zevra Therapeutics position peaked at $212K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.